Veracyte (VCYT) Current Deferred Revenue (2012 - 2026)

Veracyte has disclosed Current Deferred Revenue across 13 years of filings, most recently posting $749000.0 for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $749000.0, down 56.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $749000.0 (down 56.25% YoY), and the FY2025 annual result was $1.2 million, down 30.66% from the prior year.
• Current Deferred Revenue came in at $749000.0 for Q1 2026 at Veracyte, down from $1.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $4.9 million in Q1 2022 to a low of $417000.0 in Q3 2025.
• The 5-year median for Current Deferred Revenue is $2.2 million (2023), against an average of $2.3 million.
• Across the five-year window, Current Deferred Revenue jumped 974.45% in 2022 and slumped 79.49% in 2025, its largest moves.
• Veracyte's Current Deferred Revenue stood at $2.6 million in 2022, then slipped by 23.15% to $2.0 million in 2023, then declined by 16.68% to $1.7 million in 2024, then plunged by 30.66% to $1.2 million in 2025, then tumbled by 35.43% to $749000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $749000.0 (Q1 2026), $1.2 million (Q4 2025), and $417000.0 (Q3 2025), per Business Quant data.